Supriya Lifescience hits record revenue but walks back key guidance
Management delayed product launches and slowed order realization while doubling its capital expenditure budget for the year.
— 2 earlier stories on Supriya Lifescience Ltd. →What's new
- Q4 revenue hit a record ₹277 cr, bringing full-year revenue to ₹828 cr.
- Contrast media launch delayed to H2 FY27; cardiovascular order realization pushed over 2-3 years.
- FY26 capex reached ₹152 cr, nearly double the previously guided ₹80-90 cr range.
Why this matters
Supriya's record revenue is overshadowed by a series of missed targets and shifted timelines. When management doubles its capex spend while simultaneously pushing back revenue-generating milestones, it signals a disconnect between planning and execution. The sudden downgrade of whey protein expectations further clouds the near-term outlook.
What we're watching
- Whether the H2 FY27 timeline for contrast media holds.
- The impact of the higher-than-expected capex on free cash flow.
- Management's ability to meet revised cardiovascular volume targets.
The full read
Supriya Lifescience closed FY26 with a record ₹277 crore in Q4 revenue, a 50% jump from the prior year. While the top-line growth is strong, the earnings call revealed a pattern of missed expectations. Management pushed the launch of its contrast media product to the second half of FY27 and spread the realization of a 300-metric-ton cardiovascular order book over two to three years instead of the current fiscal year. Whey protein revenue is now expected to be immaterial. Perhaps most striking is the capital expenditure, which hit ₹152 crore—nearly double the ₹80-90 crore range previously communicated to the market. Although the company secured VAI status following a US FDA inspection, the combination of higher spending and delayed revenue realization forces a reassessment of the company's near-term growth trajectory. The open question is whether these delays are isolated incidents or a sign of broader execution friction.
Questions answered
- How did Supriya's revenue perform in FY26?
- The company reported its strongest year yet, with full-year revenue reaching ₹828 crore and a record quarterly revenue of ₹277 crore for Q4.
- What guidance did management reverse during the earnings call?
- Management delayed the contrast media product launch to H2 FY27, extended the realization of a 300-metric-ton cardiovascular order book over two to three years, and stated that whey protein revenue will no longer be material in FY27.
- How much did the company spend on capital expenditure?
- Supriya spent ₹152 crore on capex in FY26, which is nearly double the ₹80-90 crore range management had previously guided.
- Did the company receive any positive regulatory news?
- Yes, the company successfully completed a US FDA inspection and received VAI (Voluntary Action Indicated) status.
Story so far
All notes on SUPRIYA →- 28 May 2026 · 12:50 PM IST Supriya Lifescience hits record revenue but walks back key guidance
- 1d ago Supriya Lifescience profit jumps 47% in Q4
- 1d ago Supriya Lifescience ends FY26 with a 50% revenue jump in Q4